Navigating anxiety and depression in patients with nAMD

My guest for this episode is Professor Tariq Aslam, Professor of Ophthalmology and Interface Technologies at the University of Manchester and a Consultant Ophthalmologist specializing in the management of retinal disease.
In this episode, Professor Aslam and I chat about how important it is to consider anxiety and depression when managing our patients with neovascular age-related macular degeneration. Our conversation covers the quick yet effective measures that Professor Aslam has implemented in his own clinic to identify patients with anxiety and depression, with tips for our listeners on how to do the same in their own busy clinics.
We also discuss how patients with anxiety and depression can be supported and referred for treatment by ensuring we, as ophthalmologists, focus on the patient and not just the retinal disease or its treatment.
If you enjoyed this episode, please listen to past episodes in the series to hear retinal experts explore how patients’ emotions, experiences, and perceptions can influence their treatment adherence and persistence, ways to engage and empower our patients, and the evolution of patient expectations in nAMD through the 21st century.
SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode!
If you want to know more about the Barometer Program’s efforts towards patient-focused care in nAMD, visit our website: https://www.amdbarometer.org/
Further information on other studies mentioned in this episode:
POPPIES study: Senra et al., Experience of anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degeneration. Am J Ophthalmol.; https://www.ajo.com/article/S0002-9394(17)30108-3/fulltext
Cimarolli et al., Anxiety and depression in patients with advanced macular degeneration: current perspectives. Clin Ophthalmol.; https://www.dovepress.com/anxiety-and-depression-in-patients-with-advanced-macular-degeneration--peer-reviewed-fulltext-article-OPTH
Sivaprasad et al., Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol.; https://www.dovepress.com/impact-of-injection-therapy-on-retinal-patients-with-diabetic-macular--peer-reviewed-fulltext-article-OPTH
Weinstein et al., Anxiety in patients with neovascular age-related macular degeneration. Ophthalmic Epidemiol.;

This podcast series is intended for HCPs, and is not intended for UK audiences.

This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.

The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.